parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11133

BAALC in dopamine neurons, braak-0.39 (p 0.297) → +0.11 (p 0.785)receipt 11140
BAALC in astrocytes, braak-0.14 (p 0.725) → -0.10 (p 0.803)receipt 11139

receipt 11140: BAALC in dopamine neurons, braak

power: full sample -0.18 (p 0.465, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.465, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.24 (p 0.332, n 18). could be the mix.
skeptic: leave-one-out range -0.27 to -0.06, sign flips 0; without severely affected donors -0.18 (p 0.465, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BAALC in dopamine neurons.

case closed: nothing better to follow up.

receipt 11139: BAALC in astrocytes, braak

power: full sample -0.08 (p 0.748, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.04 (p 0.874, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.07 (p 0.794, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to +0.02, sign flips 2; without severely affected donors -0.08 (p 0.748, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for BAALC in astrocytes.

case closed: nothing better to follow up.

loading the receipts